The management of depression: the implications for managed care--roundtable discussion: Part 2.
One of the most commonly utilized drug classes today is antidepressant therapy, which accounts for billions of dollars in spending. Pharmacoeconomic tools may play an influential role in formulary decision making, particularly in this drug class. In part 2 of the roundtable discussion, a pharmacoeconomic model is presented that may clarify the health economic effects of placing serotonin-norepinephrine reuptake inhibitors on the drug formulary, particularly in the context of other antidepressant medications.
Arikian
S
S
Casciano
J
J
Kang-Cipolla
L
L
Vodoor
M
M
Grubin
M
M
Clark
D
D
Waugh
W
W
Kelsey
J
J
Osborn
L W
LW
D000928:Antidepressive Agents / Q000191:economics* / Q000627:therapeutic use; D002017:Budgets; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D005260:Female; D005569:Formularies as Topic; D006801:Humans; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D008605:Mental Health Services / Q000191:economics*; D015201:Meta-Analysis as Topic; D017059:Models, Econometric; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors